This report was first published by Endpoints News. To see the original version, click here
Sanofi is replacing its CEO Paul Hudson with Merck KGaA’s Belén Garijo following several years of pipeline setbacks and the looming prospect of biosimilar competition for Dupixent.
The company’s board decided not to renew Hudson’s director mandate, according to a Thursday release. Head of general medicines Olivier Charmeil will take over as interim CEO after Hudson’s last day on Feb. 17. Garijo will officially step into her role on April 29.
您已阅读17%（534字），剩余83%（2671字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。